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The activities of osteoclasts, which degrade bone, and osteoblasts, which form bone, 
are coordinated to maintain bone homeostasis. Zhao et al. (2006) now demonstrate 
bidirectional signaling between these two cell populations via the transmembrane ligand 
ephrinB2 expressed by osteoclasts and its receptor EphB4 expressed by osteoblasts. 
Such bidirectional signaling limits osteoclast activity while stimulating osteoblast 
differentiation.Remodeling of bone involves resorp-
tion of bone by osteoclasts followed 
by the differentiation and activity 
of osteoblasts, the cells that build 
bone (Hattner and Frost, 1962). The 
molecular mechanisms responsi-
ble for the cellular communication 
between osteoclasts and osteob-
lasts that control bone homeostasis 
remain one of the central issues in 
bone cell biology. A recent paper in 
Cell Metabolism by Zhao et al. (2006) 
now suggests that ephrin signaling is 
critical to the two-way communica-
tion between osteoclasts and oste-
oblasts.
Resorption of bone by osteoclasts 
is stimulated by systemic hormones 
including parathyroid hormone and 
cytokines, such as interleukin-1. 
These hormones stimulate osteoclast 
formation and activation indirectly 
by stimulating osteoblasts to pro-
duce soluble and membrane bound 
proteins, such as RANKL (receptor 
activator of NF-κB ligand) and mac-
rophage colony-stimulating factor 
(M-CSF). The intracellular signaling 
molecules responsible for mediat-
ing the effects of these two critical 
factors have been well characterized 
over the past decade (Teitelbaum 
and Ross, 2003).
However, the other aspect of bone 
remodeling that has baffled inves-
tigators is the complex signaling 
that regulates osteoblast chemo-
taxis, proliferation, differentiation, 
and function following resorption 
by osteoclasts. Bone resorption 
ceases in sites of bone remodeling, and osteoblasts are attracted to the 
bone “defects” induced by resorp-
tion and then remodel and reform the 
bone to repair them. This coupling 
of osteoclastic bone resorption and 
osteoblastic bone formation is of 
great importance because all of the 
known diseases of bone that result 
in changes in bone mass are due to 
specific aberrations of this coopera-
tive process. Thus, bone diseases 
and the drugs used to treat them 
involve or target elements of osteo-
clast/osteoblast coupling.
A number of mechanisms have 
been proposed to explain osteo-
clast/osteoblast coupling. One the-
ory, now discounted, is that osteo-
clasts and osteoblasts are in the 
same lineage, that is, osteoblasts 
are derived from osteoclasts (Ras-
mussen et al., 1974). Others have 
proposed that growth factors, such 
as Insulin-like Growth Factor-1 and 
Transforming Growth Factor β, that 
are released from the bone matrix 
as a consequence of resorption are 
responsible for the events involved 
in bone formation by osteoblasts 
(Hayden et al., 1995). This concept 
has not yet been disproved, although 
the growth factors implicated have 
effects above and beyond those nec-
essary to mediate coupling. A third 
theory is that osteoclasts, as they 
cease resorption, release factors 
that are responsible for subsequent 
cellular events (Parfitt et al., 1996). 
The notion of osteoclast-to-osteob-
last coupling is supported by studies 
with genetically engineered animals Cell 126, Asuch as mice with a disrupted SHP-
ras-MAPK pathway and mice lacking 
osteoprotegerin (OPG), a secreted 
protein related to the tumor necrosis 
factor receptor family. These mice 
exhibit enhanced bone formation 
following an increase in osteoclast 
activity. Based on these observa-
tions, it has recently been proposed 
that the initiation of bone formation 
requires osteoclasts to be transiently 
activated to enable them to produce 
the coupling activity (Martin and 
Sims, 2005).
However, an entirely different 
explanation for the coupling between 
osteoclasts and osteoblasts during 
bone remodeling is now presented 
by Zhao and colleagues (2006). 
The authors use mouse models to 
demonstrate forward and reverse 
(better termed bidirectional) signal-
ing between osteoclasts and oste-
oblasts. This bidirectional signaling 
is mediated by the transmembrane 
ephrinB2 ligand in osteoclasts and 
EphB4, a tyrosine kinase receptor, 
in osteoblasts. Their results suggest 
that these molecules may account 
for some of the critical, albeit unex-
plained, events during normal bone 
remodeling, namely the cessation 
of osteoclast activity mediated by 
osteoblasts and the coupling of new 
osteoblastic bone formation to the 
resorption of bone by osteoclasts.
There are two classes of ephrins, 
the B class (ephrin B1 to B3) are 
ligands for EphB tyrosine kinase 
receptors (B1 to B6), whereas class 
A ephrins (A1 to A5) are ligands for ugust 11, 2006 ©2006 Elsevier Inc. 441
Figure 1. Ephrin-Eph Signaling and Bone Homeostasis
Osteoclasts are responsible for the resorption of a localized packet of bone, and when they 
cease their activity, a team of osteoblasts is attracted to the resorption site, where they prolifer-
ate, differentiate, and then reform the packet of bone. (Inset) Ephrin-Eph forward signaling from 
osteoclasts to osteoblasts may be responsible for driving the formation of the new bone packet, 
and ephrin-Eph reverse signaling may be responsible for the cessation of continued bone resorp-
tion by osteoclasts.GPI-anchored EphA receptors (A1 
to A10). Ephrins have the capacity 
for bidirectional signaling. That is, 
when a cell expressing an ephrin 
receptor contacts a cell expressing 
an ephrin ligand, signals are trans-
duced into both the ephrin receptor-
expressing cell (forward signaling) 
and the ephrin ligand-expressing cell 
(reverse signaling). This type of sig-
naling induces various cytoskeletal 
responses including remodeling of 
F actin fibers and focal adhesions in 
axonal pathfinding. Additional func-
tions for ephrin and ephrin receptors 
in other cell types include the regula-
tion of tissue morphogenesis, neuro-
nal plasticity, immune response, and 
angiogenesis (Wilkinson, 2000).
In bone biology, ephrinB and EphB 
receptors control patterning of the 
developing skeleton (Compagni et 
al., 2003), and disruption of ephrin 
signaling is implicated in a syndrome 
called craniofrontonasal syndrome 
(CFNS [MIM 304110]) (Wieland et al., 
2004). Patients affected by this dis-
ease display skeletal abnormalities 
including craniofacial, thoracic, and 
limb defects. Similarly, mice lacking 
ephrinB1 display defects of the axial 
and appendicular skeleton, such as 
the asymmetric attachment of ribs, 442 Cell 126, August 11, 2006 ©2006 Elthe absence of joints, and polydac-
tyly (Twigg et al., 2004).
The study of Zhao et al. focuses 
on ephrinB2 and EphB4 and their 
effects on bone remodeling in adult 
mice. EphrinB2 and ephrinB1 are 
expressed by osteoclasts in the 
absence of any detectable Eph recep-
tor, whereas osteoblasts express 
both ephrins and Eph receptors. 
Using osteoblast-osteoclast coc-
ulture assays, as well as loss- and 
gain-of-function studies in vitro, the 
authors demonstrated that reverse 
signaling from EphB4 in osteoblasts 
to ephrinB2 in osteoclast progeni-
tors leads to the inhibition of osteo-
clast differentiation. Manipulation of 
the cytoplasmic region of ephrinB2 
allowed the authors to demonstrate 
that this inhibitory signal is mediated 
via interaction with PDZ domain pro-
teins but not by tyrosine phospho-
rylation, thus raising the possibil-
ity that PDZ domain proteins may 
be useful drug targets. Moreover, 
molecular analyses revealed that 
ephrinB2 reverse signaling in osteo-
clasts requires inhibition of Fos and 
NFATc1 transcription. The authors 
surprisingly found that mice lacking 
ephrinB2 specifically in osteoclasts 
did not have a significant bone phe-sevier Inc.notype, likely due to the redundancy 
of ephrinB1 and ephrinB2.
In the second part of the study, 
Zhao et al. demonstrated that for-
ward signaling between the extra-
cellular domains of ephrinB2 and 
EphB4 in osteoblasts stimulates 
their differentiation, a process that 
may be dependent on RhoA inac-
tivation in osteoblasts. In addition, 
forced expression of EphB4 in oste-
oblasts in vivo increased bone mass 
by enhancing bone formation and 
decreasing bone resorption. These 
results confirm that EphB4 has a 
positive effect on osteoblast differ-
entiation and indicate that osteoclast 
differentiation and function are sup-
pressed in these transgenic mice. 
Moreover, they show that this pheno-
type is independent of any effect on 
RANKL, CSF-1, or OPG. Thus, in the 
scenario presented by Zhao et al., 
reverse signaling from osteoblasts 
to osteoclasts attenuates osteoclast 
differentiation, and forward sign-
aling from osteoclasts to osteob-
lasts favors bone formation at sites 
where bone resorption had recently 
occurred (Figure 1).
It is interesting that in the study 
by Zhao et al., mice that condi-
tionally lack ephrinB2 do not have 
a bone phenotype, which sug-
gests a potential role of ephrinB1 
in bone biology. Yet, as EphB4 
binds only to ephrinB2, if ephrinB1 
has a role in bone remodeling it 
must involve binding to an EphB 
receptor in osteoblasts other than 
EphB4. Moreover, the involvement 
of RhoA in EphB4 forward signal-
ing will need to be confirmed. For 
example, expressing active RhoA in 
osteoblasts may block the ability of 
ephrinB to promote osteoblast dif-
ferentiation. EphB4 and ephrinB2 
downstream signaling pathways 
will also need to be defined to 
identify potential new therapeutic 
agents aimed at uncoupling bone 
formation and resorption and thus 
achieve an anabolic response that 
could complement the anticata-
bolic drugs available today.
This study raises a number of other 
additional general questions that will 
be important to understanding the 
specific role of ephrins in bone biol-
ogy. For example, how is expres-
sion of ephrinB2 and EphB4 regu-
lated? Is their expression regulated 
by systemic factors or local factors 
that modulate bone remodeling? 
What is their relationship to com-
mon signaling pathways and other 
important genes involved in osteo-
clast and osteoblast differentiation? 
What is their relationship to the other 
molecular mechanisms proposed for 
coupling, including growth factors, 
and are these mechanisms mutually 
exclusive? Is this a common path-
way utilized by all regulators of bone 
remodeling? Do cancer cells use 
similar bidirectional mechanisms to 
survive, proliferate, and/or use these 
mechanisms to cause the aberrations Integrins are heterodimeric cell 
surface receptors used by cells to 
interact with the extracellular matrix 
(ECM). In addition to performing a 
structural role, integrins are major 
sites of signal initiation and modu-
lation. In particular, integrins and 
receptor tyrosine kinases (RTKs) 
form a cooperative signaling net-
work to regulate various biological 
processes (Hynes, 2002; Miranti and 
Brugge, 2002). For instance, integrin 
adhesion promotes activation of sev-
eral RTKs, including the epidermal 
growth factor receptor (EGFR). Con-
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Integrins modulate signaling b
is not clear. Guo et al. (2006) 
in the formation of mammary 
proliferation and adhesion dowin osteoclast/osteoblast coupling 
that are characteristic of osteolytic 
and osteoblastic bone metastasis? 
The results of this provocative study 
have certainly provided the foun-
dation for many new studies in this 
complex field.
REFEREncES
Compagni, A., Logan, M., Klein, R., and Ad-
ams, R.H. (2003). Dev. Cell 5, 217–230.
Hattner, R., and Frost, H.M. (1962). J. Surg. 
Res. 2, 262–267.
Hayden, J.M., Mohan, S., and Baylink, D.J. 
(1995). Bone 17, 93S–98S.
Martin, T.J., and Sims, N.A. (2005). Trends 
Mol. Med. 11, 76–81.
Parfitt, A.M., Mundy, G.R., Roodman, G.D., Cell 126, A
versely, RTKs affect cell adhesion, 
spreading, and migration by regulat-
ing integrin localization and activa-
tion. Cooperative signaling between 
RTKs and integrins may also have 
a role in cancer. Even though aber-
rant activation of RTKs and changes 
in integrin expression are involved in 
epithelial malignancies (carcinoma), 
it remains unclear how cooperation 
between integrins and RTKs regu-
lates the initiation of tumor formation 
and progression to carcinoma.
In this issue of Cell, Guo et al. 
(2006) establish that α6β4 integrin, 
β4 Integrin an A
sis
 Laboratory, Cold Spring Harbor, NY 11724, 
y growth factor receptors, but th
now demonstrate that α6β4 int
tumors and discover distinct pa
nstream of the ErbB2-integrinHughes, D.E., and Boyce, B.F. (1996). J. Bone 
Miner. Res. 11, 150–159.
Rasmussen, H., Bordier, P., Kurokawa, K., Na-
gata, N., and Ogata, E. (1974). Am. J. Med. 
56, 751–758.
Teitelbaum, S.L., and Ross, F.P. (2003). Nat. 
Rev. Genet. 4, 638–649.
Twigg, S.R., Kan, R., Babbs, C., Bochukova, 
E.G., Robertson, S.P., Wall, S.A., Morriss-
Kay, G.M., and Wilkie, A.O. (2004). Proc. Natl. 
Acad. Sci. USA 101, 8652–8657.
Wieland, I., Jakubiczka, S., Muschke, P., Co-
hen, M., Thiele, H., Gerlach, K.L., Adams, 
R.H., and Wieacker, P. (2004). Am. J. Hum. 
Genet. 74, 1209–1215.
Wilkinson, D.G. (2000). Int. Rev. Cytol. 196, 
177–244.
Zhao, C., Irie, N., Takada, Y., Shimoda, K., Mi-
yamoto, T., Nishiwaki, T., Suda, T., and Mat-
suo, K. (2006). Cell Metab. 4, 111–121. ugust 11, 2006 ©2006 Elsevier Inc. 443
which binds to laminin in the ECM, is 
required for mammary tumorigenesis 
induced by expression of ErbB2, a 
member of the EGFR family of RTKs. 
ErbB2 is a dominant oncogene in 
breast cancer, and it is amplified in 
25%–30% of human breast cancers. 
Amplification of ErbB2 correlates with 
poor clinical prognosis in patients 
whose cancer has progressed to the 
lymph nodes. ErbB2 is also the tar-
get of the drug Herceptin (Citri and 
Yarden, 2006). Guo and colleagues 
exploited two mouse models, one 
that has a targeted deletion of the 
ccomplice 
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